Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Conference

Armstrong, Terri S, Wefel, Jeffrey S, Wang, Meihua et al. (2013). Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma . JOURNAL OF CLINICAL ONCOLOGY, 31(32), 4076-+. 10.1200/JCO.2013.49.6067

Open Access International Collaboration

cited authors

  • Armstrong, Terri S; Wefel, Jeffrey S; Wang, Meihua; Gilbert, Mark R; Won, Minhee; Bottomley, Andrew; Mendoza, Tito R; Coens, Corneel; Werner-Wasik, Maria; Brachman, David G; Choucair, Ali K; Mehta, Minesh

sustainable development goals

authors

date/time interval

  • November 17, 2011 -

publication date

  • November 10, 2013

webpage

published in

keywords

  • BRAIN
  • EORTC QLQ-BN20
  • Life Sciences & Biomedicine
  • NEUROCOGNITIVE FUNCTION
  • NORMATIVE DATA
  • Oncology
  • QUALITY-OF-LIFE
  • REPORTED OUTCOMES
  • SYMPTOMS
  • Science & Technology
  • VALIDATION

Location

  • Garden Grove, CA

Digital Object Identifier (DOI)

Conference

  • 16th Annual Scientific Meeting of the Society-of-Neuro-Oncology (SNO)/AANS/CNS Section on Tumors

publisher

  • AMER SOC CLINICAL ONCOLOGY

start page

  • 4076

end page

  • +

volume

  • 31

issue

  • 32